125 related articles for article (PubMed ID: 18162196)
1. Up-regulation of PPARgamma in myocardial infarction.
Fliegner D; Westermann D; Riad A; Schubert C; Becher E; Fielitz J; Tschöpe C; Regitz-Zagrosek V
Eur J Heart Fail; 2008 Jan; 10(1):30-8. PubMed ID: 18162196
[TBL] [Abstract][Full Text] [Related]
2. Cardiac protective effects of irbesartan via the PPAR-gamma signaling pathway in angiotensin-converting enzyme 2-deficient mice.
Zhang ZZ; Shang QH; Jin HY; Song B; Oudit GY; Lu L; Zhou T; Xu YL; Gao PJ; Zhu DL; Penninger JM; Zhong JC
J Transl Med; 2013 Sep; 11():229. PubMed ID: 24067190
[TBL] [Abstract][Full Text] [Related]
3. Expression of renin-angiotensin system and peroxisome proliferator-activated receptors in alcoholic cardiomyopathy.
Jing L; Li WM; Zhou LJ; Li S; Kou JJ; Song J
Alcohol Clin Exp Res; 2008 Nov; 32(11):1999-2007. PubMed ID: 18783396
[TBL] [Abstract][Full Text] [Related]
4. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.
Clasen R; Schupp M; Foryst-Ludwig A; Sprang C; Clemenz M; Krikov M; Thöne-Reineke C; Unger T; Kintscher U
Hypertension; 2005 Jul; 46(1):137-43. PubMed ID: 15939809
[TBL] [Abstract][Full Text] [Related]
5. Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorγ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension.
Kusunoki H; Taniyama Y; Rakugi H; Morishita R
J Am Heart Assoc; 2013 Apr; 2(2):e000103. PubMed ID: 23608606
[TBL] [Abstract][Full Text] [Related]
6. Irbesartan enhances GLUT4 translocation and glucose transport in skeletal muscle cells.
Kobayashi T; Akiyama Y; Akiyama N; Katoh H; Yamamoto S; Funatsuki K; Yanagimoto T; Notoya M; Asakura K; Shinosaki T; Hanasaki K
Eur J Pharmacol; 2010 Dec; 649(1-3):23-8. PubMed ID: 20826135
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II receptor blocker irbesartan attenuates cardiac dysfunction induced by myocardial infarction in the presence of renal failure.
Watanabe R; Suzuki J; Wakayama K; Kumagai H; Ikeda Y; Akazawa H; Komuro I; Isobe M
Hypertens Res; 2016 Apr; 39(4):237-44. PubMed ID: 26657004
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.
Schupp M; Janke J; Clasen R; Unger T; Kintscher U
Circulation; 2004 May; 109(17):2054-7. PubMed ID: 15117841
[TBL] [Abstract][Full Text] [Related]
9. Combined effects of irbesartan and carvedilol on expression of tissue factor and tissue factor pathway inhibitor in rats after myocardial infarction.
Yu J; Zhao J; Liu W; Ge Z; Du Y
Heart Vessels; 2011 Nov; 26(6):646-53. PubMed ID: 21229253
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation.
Janke J; Schupp M; Engeli S; Gorzelniak K; Boschmann M; Sauma L; Nystrom FH; Jordan J; Luft FC; Sharma AM
J Hypertens; 2006 Sep; 24(9):1809-16. PubMed ID: 16915030
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle.
Ambrose J; Pribnow DG; Giraud GD; Perkins KD; Muldoon L; Greenberg BH
J Cardiovasc Pharmacol; 1999 Mar; 33(3):433-9. PubMed ID: 10069680
[TBL] [Abstract][Full Text] [Related]
12. [Effects of combination therapy with angiotensin I-converting enzyme inhibitor and angiotensin 1 receptor antagonist on ventricular remodeling and expression of endothelial nitric oxide synthase].
Zhang RY; Huang YL; Sun YH
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(15):1053-6. PubMed ID: 16029550
[TBL] [Abstract][Full Text] [Related]
13. Irbesartan treatment up-regulates hepatic expression of PPARalpha and its target genes in obese Koletsky (fa(k)/fa(k)) rats: a link to amelioration of hypertriglyceridaemia.
Rong X; Li Y; Ebihara K; Zhao M; Kusakabe T; Tomita T; Murray M; Nakao K
Br J Pharmacol; 2010 Aug; 160(7):1796-807. PubMed ID: 20649581
[TBL] [Abstract][Full Text] [Related]
14. AT1 receptor blockade limits myocardial injury and upregulates AT2 receptors during reperfused myocardial infarction.
Jugdutt BI; Menon V
Mol Cell Biochem; 2004 May; 260(1-2):111-8. PubMed ID: 15228092
[TBL] [Abstract][Full Text] [Related]
15. Interaction between irbesartan, peroxisome proliferator-activated receptor (PPAR-γ), and adiponectin in the regulation of blood pressure and renal function in spontaneously hypertensive rats.
Afzal S; Sattar MA; Johns EJ; Abdulla MH; Akhtar S; Hashmi F; Abdullah NA
J Physiol Biochem; 2016 Dec; 72(4):593-604. PubMed ID: 27405250
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity.
Schupp M; Clemenz M; Gineste R; Witt H; Janke J; Helleboid S; Hennuyer N; Ruiz P; Unger T; Staels B; Kintscher U
Diabetes; 2005 Dec; 54(12):3442-52. PubMed ID: 16306360
[TBL] [Abstract][Full Text] [Related]
17. Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor γ.
Takai S; Jin D; Miyazaki M
J Pharmacol Sci; 2011; 116(3):309-15. PubMed ID: 21691037
[TBL] [Abstract][Full Text] [Related]
18. AT1 receptor antagonist therapy preferentially ameliorated right ventricular function and phenotype during the early phase of remodeling post-MI.
Nguyen QT; Colombo F; Clement R; Gosselin H; Rouleau JL; Calderone A
Br J Pharmacol; 2003 Apr; 138(8):1485-94. PubMed ID: 12721104
[TBL] [Abstract][Full Text] [Related]
19. Effects of irbesartan on the growth and differentiation of adipocytes in obese zucker rats.
Di Filippo C; Lampa E; Tufariello E; Petronella P; Freda F; Capuano A; D'Amico M
Obes Res; 2005 Nov; 13(11):1909-14. PubMed ID: 16339122
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of angiotensin II type 2 receptor and limitation of myocardial stunning by angiotensin II type 1 receptor blockers during reperfused myocardial infarction in the rat.
Jugdutt BI; Menon V
J Cardiovasc Pharmacol Ther; 2003 Sep; 8(3):217-26. PubMed ID: 14506547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
